Gilder Gagnon Howe & CO LLC Arcutis Biotherapeutics, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $7.02 Billion
- Q1 2025
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 4,096,051 shares of ARQT stock, worth $54.8 Million. This represents 0.91% of its overall portfolio holdings.
Number of Shares
4,096,051
Previous 3,902,991
4.95%
Holding current value
$54.8 Million
Previous $54.4 Million
17.83%
% of portfolio
0.91%
Previous 0.63%
Shares
5 transactions
Others Institutions Holding ARQT
# of Institutions
251Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$153 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$152 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$147 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$118 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$115 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $806M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...